指南与共识睡眠呼吸障碍

促觉醒药物临床应用中国专家共识

Chinese expert consensus on the clinical application of wake-promoting agents
RSS 订阅 · 指南共识 · 呼吸支持与睡眠 · 2026-02-03

促觉醒药物主要兴奋大脑皮层、促进觉醒,用于治疗发作性睡病等所致日间过度嗜睡(EDS)或特殊任务中维持警觉。国内外已批准多种促觉醒药物用于发作性睡病、阻塞性睡眠呼吸暂停等相关EDS,但缺乏专门临床应用共识。中国睡眠研究会睡眠障碍专业委员会组织多学科专家,基于国内外最新临床证据及相关指南制定本共识,全面综述作用机制、获批适应证、临床研究、剂量及不良反应,并就药物选择、滴定及特殊人群应用提出推荐。

要点

  • 促觉醒药物用于发作性睡病、OSA等所致日间过度嗜睡(EDS)的治疗。
  • 共识涵盖药物机制、适应证、临床研究、剂量及不良反应。
  • 共识提供药物选择、滴定及特殊人群应用的推荐。

核心结论

  • 本共识为促觉醒药物在中国临床的合理规范化应用提供指导。

研究设计与样本

  • 中国睡眠研究会睡眠障碍专业委员会组织多学科专家,基于国内外最新临床证据及相关指南制定本共识。

主要发现

  • 共识全面综述了多种促觉醒药物的作用机制、获批适应证、临床研究、剂量及不良反应。

关键数值与推荐

  • 共识就不同病因所致日间过度嗜睡的药物选择、滴定及特殊人群应用提出推荐。

临床怎么用

  • 临床可依据本共识规范促觉醒药物在日间过度嗜睡患者中的选择、滴定及特殊人群应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zhonghua Nei Ke Za Zhi. 2026 Feb 1;65(2):121-141. doi: 10.3760/cma.j.cn112138-20250821-00497. ABSTRACT Wake-promoting agents mainly excite the cerebral cortex and promote wakefulness. They are clinically used to treat excessive daytime sleepiness (EDS) caused by narcolepsy and other diseases, or to maintain alertness during special tasks. In recent years, a variety of wake-promoting agents have been approved for the treatment of EDS related to narcolepsy, obstructive sleep apnea and other diseases at home and abroad. However, a dedicated expert consensus on the clinical application of wake-promoting agents remains lacking. To facilitate the rational and standardized clinical application of wake-promoting agents in China, the Sleep Disorders Committee of the Chinese Sleep Research Society convened a multidisciplinary panel of domestic experts. This assembly developed this consensus based on the latest clinical evidence sourced from both domestic and international research, as well as relevant guidelines and their collective clinical expertise. The consensus comprehensively reviews the mechanisms of action, approved indications, clinical studies, dosages, and adverse reactions of various wake-promoting agents. It also provides recommendations on drug selection, titration, and the use of wake-promoting agents in special populations for excessive daytime sleepiness caused by various etiologies. It has strong clinical guidance and clinical application value. PMID: 41633643 | DOI: 10.3760/cma.j.cn112138-20250821-00497

来源:指南共识 · 呼吸支持与睡眠,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 呼吸支持与睡眠:Chinese expert consensus on the clinical application of wake-promoting agents

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。